Antisense Pharma GmbH has appointed Philippe Calais, a veteran biotech executive, as its new chief executive officer. Dr Calais will succeed the interim CEO, Hubert Heinrichs, who has been leading the business since July of 2011 in addition to his primary duties as chief medical officer. Dr Calais has more than two decades of executive experience including at the Roche group and at ICI Pharmaceuticals.
Antisense Pharma announced the appointment on 10 May 2012.
Copyright 2011 Evernow Publishing Ltd